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Abstract – Introduction: Mesenchymal stem cells (MSC’s) are believed to have multipotent plasticity with the
capability to differentiate along multiple cell lineages such as cartilage, bone, tendon, muscle, and nerve. Such
multipotency has the potential to play an important role in the repair and reconstruction of multiple tissues across
a number of orthopaedic specialties. Bone marrow and fat are the most abundant and accessible source of MSC’s with
bone marrow aspirate the most commonly being reported to stimulate healing.
Methods: This review examines the current reported 20 Q2 clinical applications of bone marrow aspirate concentrate
and its effectiveness.
Results: The published studies reported techniques of collection and preparation of BMAC in addition to its applica-
tions in a number of orthopaedic sub-specialities. Studies could be sub-categorised into: techniques of extraction, pro-
cessing and microscopic examination of BMAC (31), reconstruction of osseous defects/non-union (20), treatment of
avascular necrosis (9), repair of cartilage defects (8), treatment of sports injuries and tendon injury/repair (9), injec-
tion in regenerative therapy (4), treatment of spine conditions (4) including enhancing postoperative fusion and degen-
erative disc pathology and orthopaedic oncology (4). A few published studies combined the use of platelet-rich
plasma (PRP) with BMAC (4) or compared them in different applications (5).
Conclusions: BMAC has been used in bone, cartilage and tendon injuries with encouraging results.
Key words: Bone Marrow Aspirate Concentrate, BMAC, Mesenchymal Stem Cells.
Introduction
Mesenchymal stem cells (MSCs) [1] are believed to have
multipotent plasticity with the capability to differentiate along
multiple cell lineages such as cartilage, bone, tendon, muscle
and nerve [1–6]. Such multipotency has the potential to play
an important role in the repair and reconstruction of multiple
tissues across a number of orthopaedic specialties. Bone
marrow and fat are the most abundant and accessible source
of MSCs with bone marrow aspirate the most commonly being
reported to stimulate healing [7, 8].
Bone Marrow composition
The cellular composition of bone marrow aspirate in nor-
mal subjects has been studied by Bain using light microscopy
[9]. On analysing small volumes (0.1–0.2 mL) in 50 subjects it
was found that neutrophils and erythroblasts were the dominant
cell type. Neutrophils were lower in males (32.7%) compared
with females (37.4%) but erythroblasts were greater in males
(28.1%) compared with females (22.5%), which is likely to
represent the differences in adult haemoglobin concentrations.
The other constituents included lymphocytes 13.1%,
eosinophils 2.2%, blast cells 1.4 (immature white cells), mono-
cytes 1.3% and basophils 0.1%. There was a wide variation in
the megakaryocyte percentage (platelet precursors) and this is
likely to represent the wide variation in normal ranges in the
adult population. Yamamura et al. [10] assessed the cellular
composition using laser photometry, with the mean subpopula-
tion percentages being consistent with Yamamura et al. [10].
Kim et al. found similar percentages using a flow cytometry
technique analysing 2 mL of bone marrow [11]. Although
the mechanism of cellular analysis differs the percentage of
each cell type is largely similar (Table 1) [12].*Corresponding author: mohamed.imam@aol.com
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Bone Marrow harvest
The body has numerous potential areas for bone marrow
harvest. Hyer et al. compared the iliac crest, tibia and
calcaneus as widely accessible areas and assessed the number
of osteoblastic connective tissue progenitor cells [13]. The iliac
crest yielded a higher mean concentration of osteoblastic
progenitor cells compared to the tibia and calcaneus. Gender,
smoking status and diabetes were not predictive of osteoblastic
progenitor cell concentration. However, with increasing age
there is a reduction in the fibroblast colony forming units
(CFU-F) and hence stem cells, which may have implications
on efficacy in the elderly population [13].
Bantinic et al. looked at the aspirate from the first 1 mL
and subsequent aspirates from the iliac crest. In subsequent
samples, the nucleated cell population and CFU level were 3
and 10· lower than the first 1 mL of aspirate [14]. This work
has been supported by Muschler et al. highlighting that as the
volume of aspirate from the iliac crest increases from 2 to
4 mL the number of MSCs decreases by 50% [15]. This is
likely due to the proportion of blood in the subsequent samples
diluting the concentration of progenitor cells and colony
forming units/stem cells. Muschler et al. [15] and Hernigou
et al. [16] have defined the sector rule for the aspiration of
marrow from the iliac crest, which is based on safety zones.
They studied the anatomy of the iliac bone and its adjacent
structures vulnerable to injury by the trocar when it is intro-
duced into the iliac crest. The authors used computed tomog-
raphy to examine 48 iliac crests in 24 pelvises. They divided
the iliac crest into six equal sectors from anterior to posterior
direction. The authors studied 480 trocar entry points under-
taken by six surgeons among 120 patients. They demonstrated
that the sector system consistently envisaged safe and unsafe
zones for placing the trocar in the iliac crest. They observed
increased risk of breaches on obese patients and this risk is
decreased in more experienced surgeons. Ninety-four breaches
out of 480 entry points occurred with increased risks observed
in the thinner sectors in the iliac crest. Additionally, there is
increased risk of injuring the external iliac artery in the four
most anterior sectors (1–4) especially in females. On the other
hand, posterior sectors were associated with increased risk of
sciatic nerve and gluteal vessel injury when the trocar was
inserted more than 6 cm into the posterior iliac crest. They
concluded that the sector rule is a reliable system to use for
bone marrow aspiration (BMA) [16]. Hernigou et al. in a
separate study also identified that the use of 10 mL syringes
to aspirate bone marrow was superior to 50 mL syringes.
In 30 patients the 10 mL syringe aspirations resulted in
progenitor cell concentrations on average 300% higher.
This was believed to be secondary to a larger negative pressure
generated in the 10 mL syringe which preferentiallyremoved
bone marrow cells and reduced blood contamination [17].
Bone Marrow concentration
The main concern in using BMA to stimulate tissue repair/
regeneration is that only 0.001% of nucleated cells within
BMA are MSCs [9, 18–20]. To address this issue, various
protocols have been developed to concentrate the nucleated
cell numbers to produce bone marrow aspirate concentrate
(BMAC). It is hoped that it would then have the sufficient
amount of MSCs needed to provide an effective environment
of healing and regeneration [20, 21].
Different techniques have been proposed to concen-
trate bone marrow aspirate to form BMAC. These include
the use of Ficoll density gradients in the laboratory setting
and automated, closed centrifugation systems in the clinical
setting. The exact mechanism of action of BMAC is currently
not fully understood. Potentially the MSCs contained
within BMAC will provide a direct cell source for repair of
the host tissue. Alternatively or in addition, the nucleated cells
may have a significant paracrine effect delivering various
cytokines and growth factors to orchestrate and direct host
repair [22–25].
This review examines the currently reported clinical
applications of BMAC and its effectiveness.
Methods
Eligibility
We have included all published clinical literature investi-
gating the development, techniques and applications of
BMAC. Language, design and risk of bias did not deter the
initial inclusion of any study. Our search was exclusively
limited to studies involving human subjects.
Search Strategy
A PRISMA-compliant search was carried out as published
in 2009 [26]. This included the online databases: PubMed,
EMBASE, ClinicalTrials.gov and the Cochrane library from
1960 to the end of May 2015. The Medical Subject Heading
(MeSH) terms used included: ‘‘Bone’’ AND ‘‘Marrow’’
AND ‘‘Aspirate’’ AND ‘‘Concentrate’’.
Table 1. Results of cytological analysis of bone marrow aspirate and bone marrow concentrate [12].
Bone marrow aspirate* Bone marrow concentrate* Absolute change* Relative change p-Value
Platelet count · 103/lL 31.1 208.3 177 8.7 0.002
White blood-cell count · 103/lL 36.5 267 230 7.4 0.0007
Red blood-cell count · 103/lL) 6774 3156 3617 0.5 <0.0001
* These values are presented as the mean and standard deviation. N = 10.
 The relative change is presented as the mean with the 95% confidence interval.
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Critical Appraisal
Eligible studies were independently appraised by two
authors using the Critical Appraisal Skills Program checklist.
For the purpose of narrative review, relevant studies were
included irrespective of methodology or level of evidence.
Results
Eighty-nine of the 122 (58 PubMed and 64 EMBASE)
results yielded by the preliminary search were included.
Exclusions included seven duplicate records, four letters,
22 non-orthopaedics related studies (11 vascular surgery,
10 maxillo-facial and one oncology) and two records irrelevant
to our search topic.
On searching www.ClinicalTrials.gov, we found that 28 trials
were registered. All trials examined the use of stem cells in
different orthopaedic applications (Table 2). The CASP apprai-
sal confirmed a satisfactory standard of all 89 studies [27].
The published studies reported techniques of collection and
preparation of BMAC in addition to its applications in a
number of orthopaedic sub-specialities. Studies could be sub-
categorised into: techniques of extraction, processing and
microscopic examination of BMAC (31), reconstruction of
osseous defects/non-union (20), treatment of avascular necrosis
(9), repair of cartilage defects (8), treatment of sports injuries
and tendon injury/repair (9), injection in regenerative therapy
(4), treatment of spine conditions (4) including enhancing
postoperative fusion and degenerative disc pathology and
orthopaedic oncology (4). A few published studies combined
the use of platelet-rich plasma (PRP) with BMAC (4) or
compared them in different applications (5).
Literature review
Hernigou et al. highlighted that the efficacy of BMAC is
dependent on the amount of progenitor cells in the concentrate.
They compared the quantity and concentration of these cells in
both BMA and BMAC aspirated from the iliac crest when used
for the treatment of atrophic non-union of the tibia. The BMA
contained a mean of 612 ± 134 compared to 2579 ± 1121
cells per cm3 in the BMAC group. Reduced concentration of
progenitor cells at the non-union sites was significantly
associated (p < 0.01) with non-union [28].
Different techniques have been proposed to concentrate the
marrow aspirate to form BMAC. These include the use of Ficoll
density gradients in the laboratory setting and automated,
closed centrifugation systems in the clinical setting. Although
these techniques increase the number of MSCs, they do not
significantly increase the ratio of stem cells to other nucleated
cells [20, 21, 29]. Centrifugation is the present technique of
choice for the various commercially available products used
in the clinical setting, although as shown in relation to PRP
there is significant variation in the final end products achieved.
Fortier et al. compared the constituents of PRP and BMAC,
there are reduced platelets and raised white blood cells (WBCs)
in BMAC demonstrating that this is a very different substance
to PRP with a likely different mechanism of action [12].
Bone defects
Existing common approaches to managing bone defects
involve using allograft bone or harvesting bone from a donor
site, usually iliac crest. BMAC has been used to augment this
approach with the aim of improving the incorporation of bone
graft and in some cases replace it. BMAC utilisation in
managing bone defects has been popularised as MSCs can
differentiate into osteoblasts and are able to promote
osteogenic differentiation in vitro without any osteogenic
stimuli [21–23, 28, 30].
Bone Marrow Aspirate Concentrate was used in the
treatment of atrophic non-union in 60 patients by Hernigou
et al. [28]. They reported a positive association between the
quantity of hard callus and the number (p = 0.04) and
concentration (p = 0.01) of fibroblast colony-forming (FCF)
units in the graft. In the seven non-united tibias, the concentra-
tion (p = 0.001) and the total number (p < 0.01) of progenitors
cells injected were significantly lower than in those that united.
They also reported the time interval needed to achieve union
was negatively correlated with the FCF units’ concentration
at the site of the graft (p = 0.04).
Lee et al. [22] demonstrated superior bone healing in a
randomised trial using BMAC with PRP injections during
distraction osteogenesis of the tibia in 20 patients (40 tibias).
They compared patients receiving an osteotomy site injection
of BMAC and PRP (treatment group) versus no injection
(control group). The mean cortical healing indexes were signif-
icantly higher in the treatment group (p < 0.001). Although
callus profile and type were not different between the two
groups, full weight bearing was allowed earlier in the treatment
group than in the control group (index: 0.99 months/cm
and 1.38 months/cm, respectively, p < 0.001). The main
limitation with this study is that they did not evaluate
whether the combination of BMAC or PRP has synergistic
effects on bone regeneration. This query was addressed by
Kassem [31] and Hernigou et al. [32], who revealed that the
injection of BMAC alone is efficient in the management of
non-union.
The use of BMAC with bone defects has clear potential for
use in non-union and distraction osteogenesis. However,
further trials are required to refine indications and establish a
standardised methodology of preparation and application.
Avascular necrosis
The use of BMAC in avascular necrosis (AVN) [19, 21,
33–38], particularly of the femoral head [19, 36, 37, 39–42]
has been described by a number of authors. In 2002, Hernigou
and Beaujean [19] were the first to describe a protocol for
BMAC injection combined with conventional core decompres-
sion (CD) to manage AVN of the femoral head. They studied
189 hips in which BMAC obtained from the iliac crest
was inserted into the necrotic area within the femoral head.
They reported excellent outcomes in hips at the pre-collapse
stage, with total hip replacement (THR) only warranted in
9/145 (6.2%) of the hips studied at five years follow-up.
The same cohort of patients was evaluated in a more recent
retrospective analysis [41], 94 of 534 (17%) hips needed a
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Table 2. Clinical trials of stem cells and orthopaedic applications registered at ClinicalTrials.gov (June 2015).
Phase Cell type Status Condition
Number
enrolled Institute Completion Access No.
Stem cells Enrolling Hip arthroplasty 50 University of
Nebraska
April 2012 NCT01366911
II MSCs Recruiting Knee cartilage
injuries
16 University of
Jordan
June 2015 NCT02118519
II/III Autologous
MSCs
Unknown Articular cartilage
defects
25 Cairo University December 2014 NCT00891501
II Autologous
MSCs
Not recruiting Achilles
tendinopathy
10 University College
London
May 2016 NCT02064062
II Allogeneic
MSCs
Unknown Osteoarthritis 60 Stempeutics
Research
Pvt Ltd
July 2014 NCT01453738
0 Allogeneic
UCMSCs
Enrolling Osteochondral
lesion of talus
28 Samsung Medical
Centre
August 2015 NCT02338375
I/II MSCs Completed Meniscectomy 55 Mesoblast April 2008 NCT00225095
I MSCs Unknown Bone healing 5 University of
Indonesia
December 2014 NCT01725698
II MSCs Recruiting Hip avascular
necrosis
30 Universidad
Autónoma de
Madrid
February 2017 NCT02065167
I/II Autologous
MSCs
Unknown Chondral knee
defects
30 Fundación para
la Investigación
Biomédica del
Hospital
Universitario
La Paz
June 2012 NCT01399749
II Allogeneic
MSCs
Recruiting Tibial closed
diaphyseal
fractures
40 Royan Institute December 2015 NCT02140528
I/II MSCs Active,
not
recruiting
Knee osteoarthritis 30 University of
Navarra
November 2014 NCT02123368
Enrolling Posterolateral
lumbar fusion
60 University of Utah January 2016 NCT01409954
Autologous
MSCs
Completed Fracture non-union
healing
35 Keele University October 2011 NCT02177565
I/II MSCs/PRP Recruiting OA knee 24 Aditya K Aggarwal June 2014 NCT01985633
I Autologous
MScs
Completed Ankle joint
osteoarthritis
6 Royan Institute September
2011
NCT01436058
III BMMSCs Recruiting Talar osteochondral
lesion
140 Istituto Ortopedico
Rizzoli
June 2015 NCT02005861
I BMMSCs Completed Bone cyst 6 Royan Institute October 2011 NCT01207193
II/III MSCs Withdrawn Benign bone
lesion
0 Emory University March 2010 NCT00851162
Allogeneic
MSCs
Active,
not
recruiting
Subtalar
arthrodesis
140 AlloSource February 2017 NCT01413061
I/II Autologous
MSCs
Active,
not
recruiting
Enhance bone
healing
30 Institut National
de la Santé et
de la Recherche
Médicale, France
November 2015 NCT01842477
III Autologous
osteoblasts
Recruiting Osteonecrosis 130 Bone Therapeutics
S.A.
June 2017 NCT01529008
II/III Autologous
MSCs
Recruiting Non-union
treatments
60 Royan Institute August 2017 NCT02448849
MSCs Unknown Osteoarthritis 30 University of
Dresden
December 2010 NCT01038596
(continued on next page)
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THR at a mean follow-up of 13 years. Of these, 69 hips (18%)
demonstrated complete resolution of the necrotic area on
magnetic resonance imaging (MRI). These findings are
similar to those reported by Martin et al. who used BMAC
and PRP following minimally invasive CD of the femoral head
(FH) for AVN in 77 hips [43].
Hendrich et al. [44] used autologous BMAC in the
management of AVN in 37 femoral heads and 32 areas of
AVN in other locations. The study also included 12 non-unions
and 20 other bone defects. The injection of BMAC was
performed as part of a CD. They reported that 84/101(83%)
of patients were highly satisfied, 7/101(6.9%) moderately
satisfied and 1/101(1%) expressed poor satisfaction after a
mean follow-up period of 14 months (2–24 months). In their
opinion, the preparation of the BMAC within the operating
theatre was a viable one-step autologous cell therapy for bone
regeneration [44].
In a prospective randomised controlled trial undertaken
by Sen et al. [45], 51 hips with AVN in 40 patients were
randomly divided into two treatment groups. Twenty-six hips
were managed with CD and 26 hips were treated with BMAC
injection. The Harris Hip Score and mean hip survival
were significantly better in the BMAC group (p < 0.05).
In the largest study carried out by Zhao et al., 100 patients
were recruited. Fifty-one hips underwent CD while 53 hips
were managed by BMAC injection. In the CD group,
10/51 (20%) of hips compared to 2/53 (3.7%) of hips in
the BMAC group collapsed and finally required a second
surgery [45].
In summary, BMAC injection yields satisfactory outcomes
in AVN of the femoral head, early diagnosis and treatment
prior to bone collapse are linked with better results.
Cartilage defects
The repair of cartilage defects in animal models is
well established. This has been extended to human studies
with Gobbi et al. [46] using a single-step technique with
BMAC placed on a collagen matrix in 15 patients treated
for grade 4 cartilage defects in the knee at 24 months
follow-up. Patients showed significant improvement in
Visual Analogue Scale (VAS), International Knee Docu-
mentation Committee score (IKDC) and Knee injury and
Osteoarthritis Outcome Score (KOOS) at final follow-up
(p < 0.005). Superior outcomes were reported in patients
with solitary cartilage defects and those with small lesions.
MRI and histology confirmed hyaline-like tissue coverage
of the lesions.
The use of BMAC as a single-step technique for the
reconstruction of cartilage defects of the talus has been
compared to open or arthroscopic autologous chondrocyte
implantation (ACI) by Giannini et al. [47]. Eighty-one patients
with an average age of 30 ± 8 years were reported. In both
treatment groups, a hyaluronic acid membrane was used.
A second look arthroscopy was undertaken in all patients with
a biopsy at 12 months postsurgery. For all groups the
mean American Orthopaedic Foot and Ankle Society (AOFAS)
score improved significantly (p < 0.0005) at an average of
59.5 ± 26.5 months. There were no significant differences in
the change of AOFAS scores between the three groups.
Histological evaluations emphasised the formation of type II
collagen and proteoglycan expression. However, BMAC
provided the advantage of permitting a noticeable decrease
in morbidity as a ‘‘one-step’’ technique.
A nonrandomised prospective comparative trial by
Gobbi et al. [48] compared the outcome of matrix-induced
autologous chondrocyte implantation (MACI) versus BMAC
implantation, using the same hyaluronic scaffold, in the
patellofemoral joint at a minimum of three years postsurgery.
They reported no adverse or postoperative surgical complica-
tions in either group. The two groups demonstrated significant
improvement in the IKDC, KOOS as well as the VAS, and
Tegner score (p = 0.001), the IKDC score in the BMAC group
demonstrated significantly superior compared to MACI
(p = 0.015). Trochlear lesions displayed superior outcomes
when compared with the patellar lesions in the MACI group.
This observation was not found in the BMAC group, as the
location was not a prognostic factor. Complete filling of the
defect on MRI was 76% in the MACI group compared to
81% in the BMAC group [48].
There is a clear need for future research to review the
long-term outcomes of autologous chondrocyte transplantation
versus bone marrow derived MSC in the form of BMAC.
Short-term outcomes look very promising and may enhance
established techniques.
Tendon injury
Tendon injuries are common musculoskeletal presenta-
tions and the potential regeneration and repair properties of
Table 2. (continued)
Phase Cell type Status Condition
Number
enrolled Institute Completion Access No.
II MPCs Active,
not recruiting
Lumbar back
pain
100 Mesoblast July 2015 NCT01290367
I/II Autologous
MSCs
Recruiting Knee OA 12 University of
Toronto
February 2021 NCT02351011
III Allogeneic
MSCs
Recruiting Chondrogenic
discogenic
lumbar back pain
330 Mesoblast December
2017
NCT02412735
II MSCs Active, not recruiting Lumbar interbody
fusion
24 Mesoblast July 2015 NCT00996073
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BMAC have been explored with promising results. A case
series reported by Ellera Gomes et al. [49] reviewed
14 patients (nine women, five men) with full thickness rotator
cuff tears managed with transosseous sutures augmented with
BMAC utilising a mini-open technique. All patients were
followed up for a minimum of one year. They reported
significant improvement in the University of California,
Los Angeles (UCLA) score improving from 12 ± 3.0 to
31 ± 3.2 at 12 months postsurgery. There were no re-tears
reported, however six patients (42%) had high-signal intensity
at the critical zone. One revision was reported at two years
follow-up.
Hernigou et al. [50] evaluated the efficiency of BMAC
compared to that of a matched control group in augmenting
arthroscopic single row rotator cuff repair. Patients treated with
BMAC demonstrated superior outcomes with improved
healing rates and enhanced quality of the repaired tendon, as
demonstrated by ultrasound and MRI. Forty-five shoulders
(100%) of the BMAC group demonstrated tendon healing
by six months, compared to only 30 shoulders (67%) in the
control group at the same time point. Furthermore, at ten-
year follow-up, the integrity of the repair was maintained in
39 (87%) shoulders in the BMAC group compared to only
20 (44%) in the control group.
A prospective multicentre study by Centeno et al. [51]
compared the use of BMAC for the treatment of osteoarthritis
(OA) with and without rotator cuff pathology. A total of 115
shoulders were treated with BMAC injection principally for
glenohumeral OA with or without a rotator cuff tear. The mean
disabilities of the arm, shoulder and hand score [52] and VAS
improved significantly from 36.1 to 17.1 (p < 0.001) and 4.3 to
2.4 (p < 0.001), respectively. These results were consistent
with a mean subjective improvement of 48.8%. They reported
no significant adverse events at two years follow-up post-
surgery.
The use of BMAC in rotator cuff repair has shown initial
success in small studies. There is a need for larger scale studies
to fully define the potential role of BMAC’s role as an augment
and how best to deliver it at the repair site.
Conclusions
Mesenchymal Stem Cells in BMAC have the potential to
self-renew, undertake clonal expansion, and differentiate into
different musculoskeletal tissues. MSCs are also known to
have an immunoregulatory role and may enhance the normal
healing response. BMAC has been used in bone, cartilage
and tendon injuries with encouraging results. Alongside
well-designed clinical trials, further basic science work is
required to investigate the therapeutic action of BMAC.
The commercial processing of BMAC needs to be optimised
in order to achieve a consistent end product, which will provide
predicable and translatable results. The future potential of cell
characterisation in order to determine the optimum cell for
repair/regeneration of various tissue types also needs to be
explored.
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